Berberine Compounds Show Promise Against Stubborn H. Pylori
Nikhil Prasad Fact checked by:Thailand Medical News Team Aug 15, 2026 1 hour, 4 minutes ago
A natural plant compound called berberine and newer substances derived from it could offer researchers another way to fight Helicobacter pylori, the stomach bacterium linked to chronic gastritis, peptic ulcers and gastric cancer.
Berberine and advanced derivatives could weaken H. pylori by attacking bacterial survival, biofilms, drug resistance
and stomach inflammation simultaneously
Researchers behind a new narrative review examined evidence showing that berberine may do considerably more than simply slow bacterial growth. It appears capable of interfering with several survival mechanisms that allow H. pylori to remain in the stomach and resist treatment.
Researchers Examine a Growing Treatment Problem
The review was conducted by Szymon Viscardi from the Department of Pharmacology, Faculty of Medicine, Wroclaw Medical University, Poland, together with Anna Duda-Madej and Paweł Krzyżek from the Department of Microbiology, Faculty of Medicine, Wroclaw Medical University, Poland.
H. pylori infects an estimated 43% of the global population. Antibiotic resistance has complicated eradication, while biofilms, bacterial virulence and persistent inflammation can further protect the organism.
Berberine Attacks the Bacterium in Several Ways
Berberine is a natural alkaloid found in plants including Berberis, Coptis and Hydrastis. The review found evidence that berberine and its derivatives can damage bacterial membranes, reduce urease activity, interfere with bacterial movement, suppress efflux pumps that remove antimicrobial substances and disrupt biofilm formation.
Some derivatives appeared substantially more potent than native berberine. One 3,13-disubstituted berberine analogue produced minimum inhibitory concentrations of just 0.25–0.5 micrograms per milliliter against tested H. pylori strains and retained activity against multidrug-resistant clinical strains.
Importantly, this Thailand
Medical News report highlights that berberine may also weaken inflammation associated with infection. Experimental evidence indicates effects on NF-κB, MAPK and IRF8–IFN-γ inflammatory signaling, while other findings suggest improved antioxidant defenses and protection of the stomach lining.
Nanotechnology Could Make Berberine More Powerful
Native berberine has extremely poor oral bioavailability, with systemic absorption estimated at only 0.36–0.68%. Researchers are therefore exploring nanoparticles and nanomicelles designed to keep more berberine near the infection.
Berberine-loaded MEL-B nanomicelles reduced biofilm formation and established biofilm mass by about 80% in laboratory experiments. In infected mice, they produced approximately 90% greater reduction in bacterial burden than standard triple therapy.
Another berberine-based nanodrug eradicated 90.4% of mature biofilm, while a derivative formulation inhibited new biofilm formation by 99.96% at 6.25 micrograms per milliliter. However, the review
ers stressed that this striking result still requires independent confirmation.
Human Trials Offer Encouraging but Mixed Evidence
Clinical studies have reported berberine-containing treatment eradication rates ranging roughly from 70% to 90%. In one trial, a berberine-containing quadruple regimen achieved 90.1% eradication in intention-to-treat analysis compared with 86.4% using a bismuth-containing regimen.
Other trials similarly found berberine-containing combinations broadly comparable with standard treatments, although results varied according to antibiotics, acid-suppressing medicines and treatment design. Researchers therefore cannot yet determine berberine's independent clinical contribution.
Conclusions
Overall, berberine and its derivatives represent a promising multi-target approach rather than a proven replacement for antibiotics. Their ability to attack bacterial survival, virulence, biofilms and inflammation simultaneously deserves larger standardized clinical trials, particularly for difficult antibiotic-resistant infections.
The study findings were published in the peer reviewed journal: Pharmaceuticals.
https://www.mdpi.com/1424-8247/19/8/1279
Read Also:
https://www.thailandmedical.news/articles/herbs-and-phytochemicals 
Share
Tweet
Share
